Director Mastocytosis Center
Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
University of Utah School of Medicine
President and Chief Scientific Officer
Salt Lake City, Utah
Associate Professor of Medicine
Co-Director, Jeffrey Modell Research and Diagnostic Center
Director, Medication Desensitization Program
Duke University Hospital
Durham, North Carolina
Department of Medicine, Division of Allergy & Clinical Immunology
Icahn School of Medicine
New York, New York
For this Interactive Showcase™ in nonadvanced systemic mastocytosis (SM), the first activity, designed as an expert-guided poster tour, will briefly review the pathophysiological drivers of SM and their implications. Subsequently, you will watch an expert roundtable video where faculty will discuss management approaches, including recent clinical trial data on emerging targeted therapies and real-world strategies for comprehensive treatment. During the final activity you will participate in interactive case studies, applying information acquired to real-time management decisions.
Clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other clinicians who manage patients with nonadvanced SM.
- Discuss SM pathophysiology, including implications for potential clinical presentations and new targeted therapies
- Evaluate patients with nonadvanced SM to characterize symptoms, disease burdens, and results from ancillary testing
- Discuss recent clinical trial evidence for new targeted treatment options in nonadvanced SM
- Individualize ongoing therapeutic regimens for nonadvanced SM based on symptomatology, patient-reported outcomes, and shared clinical decision making
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.5 contact hour(s) (which includes 0.0 hour(s) of pharmacology).
Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Instructions for Credit
In order to obtain your CE credit, please follow the steps below at the conclusion of the activity:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.
Disclosures of Relevant Financial Relationships
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Mariana C. Castells, MD, PhD: Nothing to disclose
Tracy I. George, MD: Consulting fees: Allakos Inc, Blueprint Medicines Corporation, Bluprint Oncology Concepts, Celgene Corporation, CM Group, E Squared, Incyte Corporation, UBC (United BioSource LLC); Contracted Research: Bluepprint Medicines Corporation, Celgene Corporation, Cogent Biosciences, Inc., Deciphera Pharmaceuticals, Inc., Incyte Corporation; all received by ARUP Laboratories
Patricia L. Lugar, MD, MS: Consulting Fee: Blueprint Medicines, Grifols; Contracted Research: BioCryst, BioMarin, Blueprint Medicines, Takeda; Speakers' Bureau: Blueprint Medicines, Grifols
Anne Maitland, MD, PhD: Honoraria: Blueprint Medicines
The Global and Integritas Communication planners and managers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.